Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05889793 · ClinicalTrials.gov registry record · Phase 2
Evaluating Emetine for Viral Outbreaks (EVOLVE)
A Phase 2 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT05889793: Clinical Trial Phase 2 study, sponsored by Johns Hopkins University.
NCT05889793 is a Phase 2 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05889793, a Phase 2 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The goal of this clinical trial (phase 2/phase 3) is to evaluate the efficacy and safety of emetine administered orally for symptomatic Covid-19 patients in patients ages 30 years and above. Participants will be asked to: * Take Emetine 6mg orally for 10 consecutive days * Be monitored by healthcare staff or self-monitor for daily vital signs and symptoms * Undergo blood draws Researchers will compare the control group given placebo medicine to assess if emetine improved the symptoms of Covid-19.
Interventions
- DRUG Placebo
- DRUG Emetine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2024-05-15 |
| Est. Completion | 2025-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05889793
The ClinicalTrials.gov registry entry for NCT05889793 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05889793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05889793 about?
NCT05889793 is a clinical study titled "Evaluating Emetine for Viral Outbreaks (EVOLVE)". The goal of this clinical trial (phase 2/phase 3) is to evaluate the efficacy and safety of emetine administered orally for symptomatic Covid-19 patients in patients ages 30 years and above. Participants will be asked to: * Take Emetine 6mg orally for 10 consecutive days * Be monitored by healthcar...
What is the current status of trial NCT05889793?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2024-05-15. Estimated completion is 2025-12-15.
What interventions are being tested in trial NCT05889793?
The interventions under investigation include: Placebo (DRUG), Emetine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT05889793?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.